medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-14-62-67medsovet-1465Research ArticleЗАБОЛЕВАНИЯ ПЕЧЕНИLIVER DISEASEПолинозологический эффект урсодезоксихолевой кислоты (УДХК). Опыт примененияPolynosological effects of ursodeoxycholic acid (UDCA). Practice of usingМаховВ. М.MakhovV. M.

д.м.н., профессор

MD, Prof.

ВолодинаТ. В.VolodinaT. V.

к.б.н.

PhD in biology

ПанферовА. С.PanferovA. S.

к.м.н.

PhD in medicine

ТуркоТ. В.TurkoT. V.

к.м.н.

PhD in medicine

Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияFirst Moscow State Medical University named after I.M. SechenovRussian FederationВсероссийский научно-исследовательский институт лекарственных и ароматических растений, МоскваРоссияAll-Russian Research Institute of Medicinal and Aromatic Plants (VILAR)Russian Federation2016301220160146267Copyright © Махов В.М., Володина Т.В., Панферов А.С., Турко Т.В., 20162016Махов В.М., Володина Т.В., Панферов А.С., Турко Т.В.Makhov V.M., Volodina T.V., Panferov A.S., Turko T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1465

В статье даны сведения о сфере применения урсодезоксихолевой кислоты (УДХК). Наиболее доказательные позитивные эффекты терапии при первичном билиарном циррозе (ПБЦ) и при желчнокаменной болезни (ЖКБ). Обсуждена вероятность использования УДХК как средства профилактики ЖКБ при билиарном сладже (БС) и в группе риска – у лиц пожилого и старческого возраста. Представлены данные собственного исследования результатов применения УДХК у 32 больных с дисформией желчного пузыря (ДЖП) и БС. Прием препарата УДХК Гринтерол продемонстрировал высокую клиническую эффективность, безопасность и отсутствие побочных эффектов. 

The article tells about the indications for use of ursodeoxycholic acid (UDCA). The most significant positive effects were demonstrated in primary biliary cirrhosis (PBC) and cholelithiasis (CL). The possibility of using UDCA for CL prophylaxis during biliary sludge (BS) and in risk groups -people of elderly and senile age - is discussed. The article presents the results of the authors’ study of UDCA administration in 32 patients with gallbladder deformity (GD) and BS. Grinterol (UDCA) demonstrated high clinical efficacy, safety and no side effects. 

УДХКГринтеролпервичный билиарный циррозжелчнокаменная болезньбилиарный сладждисформия желчного пузыряUDCAGrinterolprimary biliary cirrhosischolelithiasisbiliary sludgegallbladder deformityReferencesМинушкин О.Н. Урсодезоксихолевая кислота (УДХК) в клинической практике. Медицинский совет, 2010, 1-2: 12-16. / Minushkin O.N. Ursodeoxycholic acid (UDCA) in clinical practice. Meditsinskiy Sovet, 2010; 1-2: 12-16.Минушкин О.Н. Урсодезоксихолевая кислота (УДХК) в клинической практике. Медицинский совет, 2010, 1-2: 12-16. / Minushkin O.N. Ursodeoxycholic acid (UDCA) in clinical practice. Meditsinskiy Sovet, 2010; 1-2: 12-16.Guarino MPL, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol., 2013 Aug 21, 19(31): 5029-5034.Guarino MPL, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol., 2013 Aug 21, 19(31): 5029-5034.Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol., 2014 Jul, 12(7): 1090-1100.Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol., 2014 Jul, 12(7): 1090-1100.Yamamoto R, Tazuma S, Kanno K, Igarashi Y et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: a randomized trial. J Hepatobiliary Pancreat Sci., 2016 Feb, 23(2): 132-6.Yamamoto R, Tazuma S, Kanno K, Igarashi Y et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: a randomized trial. J Hepatobiliary Pancreat Sci., 2016 Feb, 23(2): 132-6.Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol., 2013, 19(31): 5029-34.Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol., 2013, 19(31): 5029-34.Saraswat VA, Sharma BC, Agarwal DK, Kumar R, Negi TS, Tandon RK. Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol., 2004 Oct, 19(10): 1206-11.Saraswat VA, Sharma BC, Agarwal DK, Kumar R, Negi TS, Tandon RK. Biliary microlithiasis in patients with idiopathic acute pancreatitis and unexplained biliary pain: response to therapy. J Gastroenterol Hepatol., 2004 Oct, 19(10): 1206-11.Okoro N, Patel A, Goldstein M, Narahari N, Cai Q. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis. Gastrointest Endosc., 2008 Jul, 68(1): 69-74.Okoro N, Patel A, Goldstein M, Narahari N, Cai Q. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis. Gastrointest Endosc., 2008 Jul, 68(1): 69-74.Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Longterm effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol., 2006 Jul, 101(7): 1529-38.Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Longterm effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol., 2006 Jul, 101(7): 1529-38.Ивашкин В.Т., Широкова Е.Н., Маевская М.В. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015, 2: 41-57. / Ivashkin V.T., Shirokova E.N., Maevskaya M.V. et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on study of the liver on diagnostics and treatment of cholestasis. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii, 2015, 2: 41-57.Ивашкин В.Т., Широкова Е.Н., Маевская М.В. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015, 2: 41-57. / Ivashkin V.T., Shirokova E.N., Maevskaya M.V. et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on study of the liver on diagnostics and treatment of cholestasis. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii, 2015, 2: 41-57.Wijaya I. The Role of Ursodeoxycholic Acid in Acute Viral Hepatitis: an Evidence-based Case Report. Acta Med Indones., 2015 Oct, 47(4): 352-7.Wijaya I. The Role of Ursodeoxycholic Acid in Acute Viral Hepatitis: an Evidence-based Case Report. Acta Med Indones., 2015 Oct, 47(4): 352-7.Chen W, Liu JP, Gluud C. Bile acids for viral hep￾atitis. Cochrane Database of Systematic Reviews, 2007, Issue 4. Art. No.: CD003181.Chen W, Liu JP, Gluud C. Bile acids for viral hep￾atitis. Cochrane Database of Systematic Reviews, 2007, Issue 4. Art. No.: CD003181.Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol., 2013 Sep 23, 13: 140.Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol., 2013 Sep 23, 13: 140.Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet, 1999 Sep 25, 354(9184): 1053-60.Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet, 1999 Sep 25, 354(9184): 1053-60.Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev., 2002, (1): CD000551.Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev., 2002, (1): CD000551.Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysisof randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol., 2007 Aug, 102(8): 1799-807.Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysisof randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol., 2007 Aug, 102(8): 1799-807.Lindor KD, M Gershwin E, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary Biliary Cirrhosis. Hepatology, 2009, 50(1): 291-308.Lindor KD, M Gershwin E, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary Biliary Cirrhosis. Hepatology, 2009, 50(1): 291-308.Othman MO, Dunkelberg J, Roy PK. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab J Gastroenterol., 2012 Sep, 13(3): 103-10.Othman MO, Dunkelberg J, Roy PK. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Arab J Gastroenterol., 2012 Sep, 13(3): 103-10.Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50: 808-14.Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50: 808-14.Singh S, Khanna S, Pardi DS, Loftus EVJr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis., 2013 Jul, 19(8): 1631-8.Singh S, Khanna S, Pardi DS, Loftus EVJr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis., 2013 Jul, 19(8): 1631-8.Grand’Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can., 2014 Jul, 36(7): 632-41.Grand’Maison S, Durand M, Mahone M. The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. J Obstet Gynaecol Can., 2014 Jul, 36(7): 632-41.Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One, 2015 Mar 16, 10(3): e0122124.Guo T, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS One, 2015 Mar 16, 10(3): e0122124.Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, Lee JH. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract., 2016 Apr, 70(4): 302-11.Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, Lee JH. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract., 2016 Apr, 70(4): 302-11.McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther., 2011 Jul, 34(2): 146-65.McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther., 2011 Jul, 34(2): 146-65.Banerjee B, Shaheen NJ, Martinez JA et.al. Clinical Study of Ursodeoxycholic Acid in Barrett’s Esophagus Patients. Cancer Prev Res (Phila), 2016 Feb 23. pii: canprevres.0276.2015.Banerjee B, Shaheen NJ, Martinez JA et.al. Clinical Study of Ursodeoxycholic Acid in Barrett’s Esophagus Patients. Cancer Prev Res (Phila), 2016 Feb 23. pii: canprevres.0276.2015.Щербенков И.М. Возможности терапии дискинезии желчевыводящих путей. Медицинский совет, 2013, 3: 47-51. / Scherbenkov I.M. Possibilities of treatment of biliary dyskinesia. Meditsinskiy Sovet, 2013, 3: 47-51.Щербенков И.М. Возможности терапии дискинезии желчевыводящих путей. Медицинский совет, 2013, 3: 47-51. / Scherbenkov I.M. Possibilities of treatment of biliary dyskinesia. Meditsinskiy Sovet, 2013, 3: 47-51.Немцов Л.М. Фармакотерапия функцио нальных растройств билиарного тракта. Вестник фармации, 2014, 4(60): 86-100. / Nemtsov L.M. Pharmacotherapy of functional disorders of the biliary tract. Vestnik Farmatsii, 2014, 4(60): 86-100.Немцов Л.М. Фармакотерапия функцио нальных растройств билиарного тракта. Вестник фармации, 2014, 4(60): 86-100. / Nemtsov L.M. Pharmacotherapy of functional disorders of the biliary tract. Vestnik Farmatsii, 2014, 4(60): 86-100.Иванова О.И., Елизаветина Г.А., Минушкин О.Н., Ардатская М.Д. Лечебная тактика при сочетанных функциональных расстройствах кишечника и желчевыводящей системы. Эффективная фармакотерапия, 2015, 37. / Ivanova O.I., Elizavetina G.A., Minushkin O.N., Ardatskaya M.D. Therapeutic approach in combined functional disorders of the intestine and the biliary system. Effektivnaya Farmakoterapiya, 2015, 37.Иванова О.И., Елизаветина Г.А., Минушкин О.Н., Ардатская М.Д. Лечебная тактика при сочетанных функциональных расстройствах кишечника и желчевыводящей системы. Эффективная фармакотерапия, 2015, 37. / Ivanova O.I., Elizavetina G.A., Minushkin O.N., Ardatskaya M.D. Therapeutic approach in combined functional disorders of the intestine and the biliary system. Effektivnaya Farmakoterapiya, 2015, 37.Ильченко А.А. Тактика ведения больного с постхолецистэктомическим синдромом. Consilium medicum, 2009, 2: 26-28. / Il’chenko A.A. Management approach for postcholecystectomy syndrome. Consilium medicum, 2009, 2: 26-28.Ильченко А.А. Тактика ведения больного с постхолецистэктомическим синдромом. Consilium medicum, 2009, 2: 26-28. / Il’chenko A.A. Management approach for postcholecystectomy syndrome. Consilium medicum, 2009, 2: 26-28.Ильченко А.А. Билиарный сладж: причины формирования, диагностика, лечение. Consilium medicum (Гастроэнтерология), 2012, 2: 14-18. / Il’chenko A.A. Biliary sludge: causes, diagnosis, treatment. Consilium Medicum (Gastroenterology), 2012, 2: 14-18.Ильченко А.А. Билиарный сладж: причины формирования, диагностика, лечение. Consilium medicum (Гастроэнтерология), 2012, 2: 14-18. / Il’chenko A.A. Biliary sludge: causes, diagnosis, treatment. Consilium Medicum (Gastroenterology), 2012, 2: 14-18.

The authors declare that there are no conflicts of interest present.